AIM ImmunoTech Inc. filed a Form 8-K on November 18, 2026, disclosing that its 2026 Annual Meeting of Stockholders was adjourned on November 17, 2026, due to insufficient shares present or represented by proxy to constitute a quorum.
Key Highlights
- Meeting adjourned: The 2026 Annual Meeting was convened and then adjourned on November 17, 2026, without conducting any business.
- Reason for adjournment: The company disclosed that it did not have a sufficient number of shares present or represented by proxy to constitute a quorum.
- Reconvening date: The meeting is scheduled to reconvene at 11:00 A.M. Eastern Time on December 8, 2026, virtually.
- Record date unchanged: The record date for stockholder voting eligibility remains the close of business on September 28, 2026.
- No proposal changes: According to the filing, no changes have been made to the proposals to be voted on at the Annual Meeting.
- Prior voters unaffected: The filing states that stockholders who have previously submitted their proxy or otherwise voted and do not want to change their vote do not need to take any action.
AIM ImmunoTech's 2026 Stockholder Meeting Postponed Amid Quorum Shortfall
AIM ImmunoTech Inc., a Delaware-incorporated biopharmaceutical company whose common stock (par value $0.001 per share) trades on NYSE American under the ticker NYSE American:AIM, disclosed the adjournment through two items in its Form 8-K. Under Item 8.01, the company reported that the meeting was convened on November 17, 2026, and immediately adjourned because a quorum could not be established. The company cited two reasons: insufficient shares present or represented by proxy, and a desire to give stockholders additional time to review proxy materials and submit their votes.
Under Item 7.01, the company disclosed that a press release dated November 18, 2026, was furnished as Exhibit 99.1. The filing notes that the information furnished under Item 7.01 and in the press release "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934." The adjourned meeting is set to reconvene virtually on December 8, 2026, at 11:00 A.M. Eastern Time. The filing was signed by Thomas K. Equels, Chief Executive Officer, on November 18, 2026.
The company confirmed that the stockholder record date, originally set as the close of business on September 28, 2026, remains unchanged. All proposals previously presented to stockholders for a vote at the Annual Meeting remain on the agenda without modification, according to the filing.
What Was Disclosed
AIM ImmunoTech Inc. reported via Form 8-K that its 2026 Annual Meeting of Stockholders was adjourned on November 17, 2026, for lack of quorum, with the reconvened meeting scheduled for December 8, 2026. The record date and all voting proposals remain unchanged.




Please wait processing your request...